IL3RA-ADC demonstrated potent antiproliferative activity with half-maximal inhibitory concentration (IC50) values at the subnanomolar to nanomolar range in the IL3RA-positive AML (MV-4-11, MOLM-13) and HL (HDLM-2, L-428) derived cell lines, whereas little activity was observed in the tumor cell lines with low levels of or negative for IL3RA membrane expression (NCI-H292, HT). Here, IL3RA is linked to acute myeloid leukemia.